Therefore, we concluded that our results have revealed a novel mechanism underlying cholesterol-mediated vemurafenib resistance in melanoma and proved that the cholesterol-27HC-Rap1 axis is a potential target for the treatment of vemurafenib-resistant melanoma. Here, RAP1A is linked to melanoma.